KINGMAKER (01170) expects a year-on-year increase in revenue of approximately 7.9% for the first quarter.
Xinxing Group (01170) announced that as of the first quarter ending on March 31, 2026, the group's orders have shown growth, with...
KINGMAKER (01170) announced that as of the end of the first quarter of the fiscal year 2026 on March 31, the group's orders showed growth, mainly due to brand customers accelerating shipments during the 90-day tariff grace period, and the increase in orders mainly coming from the competitive cost structure of the factory in Cambodia. Based on unaudited data from the company's management accounts, the board of directors preliminarily estimates that the group's revenue for the first quarter of the 2026 fiscal year increased by approximately 7.9% compared to the same period last year.
In the short-term uncertain environment related to tariffs, the group remains vigilant and prioritizes financial health and business resilience. The group is actively discussing product development and procurement plans with brand customers. With a well-equipped production platform, the group is prepared to respond to potential new orders and actively consolidating its preparations for market recovery. Looking ahead, the group maintains a positive outlook on the long-term development prospects of CKH HOLDINGS.
Related Articles

AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.
.png)
Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.

Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
.png)
RECOMMEND

Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
26/08/2025

U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
26/08/2025

Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
26/08/2025